Logo

Suggestions

  • Cancer Disparities
  • Opinion
  • Conferences
  • News
  • Patient Corner
  • About
    • Contact
    • Article Submission
  • Top Headlines
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • GI Malignancies
      • Melanoma & Skin Cancer
      • GU Malignancies
      • Gynecologic Oncology
      • Hematologic Malignancies
      • Lung Cancer
  • Expert Opinion
  • Video News
  • New Approvals
  • Cancer Disparities
  • Patient Corner
  • Subscribe

Logo

lymphoma

FDA_Approved
June 22, 2023
New Approvals/New Drug Applications

FDA Grants Accelerated Approval to Glofitamab-gxbm for Relapsed/Refractory DLBCL

On June 15, 2023, the U.S. Food and Drug Administration approved Glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or

FDA_Approved
New Approvals/New Drug Applications

FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Large B-cell Lymphoma

On April 19, 2023, the U.S. Food and Drug Administration (FDA) approved Polatuzumab Vedotin-Piiq in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS),

May 2, 2023

FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

New Approvals/New Drug Applications

On January 27, 2023, the U.S. Food and Drug Administration approved Pirtobrutinib for adult patients with histologically confirmed relapsed or refractory Mantle cell lymphoma

Zuma 7 trial shows statistically significant overall survival benefit for yescarta

Hematologic Malignancies/Opinion

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter study for patients with

FDA_Approved
New Approvals/New Drug Applications

FDA Grants Accelerated Approval to Glofitamab-gxbm for Relapsed/Refractory DLBCL

On June 15, 2023, the U.S. Food and Drug Administration approved Glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or

More
by Staff Writer - The Cancer News
June 22, 2023
FDA_Approved
New Approvals/New Drug Applications

FDA Grants Accelerated Approval to Epcoritamab for Relapsed or Refractory Diffuse Large B-cell Lymphoma and High-Grade B-cell Lymphoma

On May 19, 2023, Epcoritamab-bysp (Epkinly, Genmab US, Inc) was granted accelerated approval by the US FDA for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising

More
by Staff Writer - The Cancer News
June 1, 2023
FDA_Approved
New Approvals/New Drug Applications

FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Large B-cell Lymphoma

On April 19, 2023, the U.S. Food and Drug Administration (FDA) approved Polatuzumab Vedotin-Piiq in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients with previously untreated diffuse

More
by Staff Writer - The Cancer News
May 2, 2023
Dr_Luke_Fletcher
Hematologic Malignancies/Opinion

The Polarix Trial and the Rise of Polatuzumab-RCHP

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center    Combination chemoimmunotherapy with the chemo regimen R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) has long stood as the standard of care

More
by Staff Writer - The Cancer News
April 21, 2023
Dr_Luke_Fletcher
Hematologic Malignancies/Opinion

Zuma 7 trial shows statistically significant overall survival benefit for yescarta

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary refractory Large b-cell lymphoma who were candidates

More
by Staff Writer - The Cancer News
March 23, 2023
FDA_Approved
New Approvals/New Drug Applications

FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

On January 27, 2023, the U.S. Food and Drug Administration approved Pirtobrutinib for adult patients with histologically confirmed relapsed or refractory Mantle cell lymphoma intolerant to two or more standard therapies, one

More
by Staff Writer - The Cancer News
January 30, 2023

your advertisement here

you may also like...

  • targeted-therapy
    Antibody Drug Conjugates
  • FDA_Approved
    FDA Approves Luspatercept-aamt for Anemia in Patients with Myelodysplastic Syndromes
  • hodgkin-lymphoma
    KEYNOTE-087: Pembrolizumab Monotherapy for Relapsed/Refractory Classical Hodgkin lymphoma
  • Overview of KEYNOTE-671 & NADIM II
  • Expert Opinion: Children’s Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse

All Categories

  • Awareness
  • Breast Cancer
  • Cancer Disparities
  • Cancer Research
  • Conference 2023
  • Conference Coverage
  • Conferences
  • Events
  • GI Malignancies
  • GU Malignancies
  • Hematologic Malignancies
  • Journal
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Nepal Cancer Center
  • New Approvals
  • New Drug Applications
  • News
  • Opinion
  • Patient Corner
  • Spotlights
  • Uncategorized
  • Updates
  • Video News
  • Volunteer Spotlight

Search By Keyword

ASCO ASCO23 award Binaytara foundation breast cancer BTF cancer cancer care cancer disparities cancer research cancer survival cancer treatment Cellular therapy CME conference Conferences continuing education Dr. Binay Shah Dr Anish Shah Dr Shipra Gandhi Expert Opinion faculty highlight FDA FDA Approval FDA approved head & neck cancer surgery in Nepal healthcare equity hematological malignancies hematologic malignancies leukemia Lung cancer lymphoma multiple myeloma Nepal cancer care oncology CME SCHD video news Volunteer

We Transform Cancer Care

Dissect complex information on cancer and disseminate knowledge to healthcare professionals, patients, and caregivers. We want to improve patient outcomes.
Cover the latest research to promote precision oncology and patient-centered care.
Questions? Contact us -
[email protected]

Social Media

Advertisement


Footer Logo
  • Facebook
  • Twitter
  • LinkedIn

© 2023 - All Rights Reserved. Binaytara Foundation

  • About
  • Submit an Article
  • Subscribe for updates
  • Editorial Board
  • Privacy Policy
  • Contact
  • Home
  • Top Headlines
    • Awareness
    • Video News
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • Melanoma & Skin Cancer
      • GI Malignancies
      • Lung Cancer
      • Hematologic Malignancies
      • Gynecologic Oncology
      • GU Malignancies
  • New in Cancer Care
  • Conferences
    • Hemotology & Oncology Conference Calendar
    • Conference Calendar
    • Conference Coverage
  • New Approvals
  • Contact us
  • Submit an article